{"id":{"repo_id":"bu","oai_identifier":"oai:open.bu.edu:2144/46643"},"canonical_url":"https://search.dev.ndltd.org/etd/bu/oai:open.bu.edu:2144/46643","repository":{"repo_id":"bu","name":"Boston University","base_url":"https://open.bu.edu/oai/request"},"display":{"title":"Next generation near infrared (NIR) and shortwave infrared (SWIR) wearables for breast cancer imaging","abstract":"Neoadjuvant chemotherapy (NAC) is a common breast cancer treatment that involves administering chemotherapy for 3-6 months prior to surgery. This treatment enables more breast-conserving surgeries and even allows for the omission of surgery in some cases. However, about 31% of patients receiving NAC do not respond to the treatment. Therefore, there is a need for real-time methods to predict treatment response and improve patient outcomes. Over the last two decades, diffuse optical imaging has been investigated as a potential solution to this problem. This noninvasive and inexpensive technology uses near or shortwave infrared (NIR or SWIR) light to illuminate tissue, and detects multiply-scattered photons. However, bulky instrumentation and complicated imaging procedures have limited the clinical adoption of this technology. Furthermore, measured biomarkers including oxy- and deoxy-hemoglobin (HbO2 and HHb, respectively), water, and lipid, have had mixed results in terms of prognostic capability. To address these limitations, a new wearable optical probe technology was developed and validated in this project, including a high-optode density NIR probe for monitoring hemodynamics and a first-generation SWIR probe for quantifying water and lipid. Measurements on tissue-mimicking channel flow phantoms confirmed the ability of the NIR probe to quantify absorption contrast in vitro, and a cuff occlusion measurement demonstrated sensitivity to HbO2 and HHb in vivo. Hemodynamic oscillations at the respiratory rate were also explored in healthy volunteers and breast cancer patients as a potential new biomarker. It was demonstrated that traditional and novel breathing-related hemodynamic metrics provide tumor contrast and can potentially track treatment response. A deep-learning algorithm was developed to extract water and lipid concentrations from multi-distance SWIR measurements. The SWIR probe was validated by comparing measured water and lipid concentrations against ground truth values in emulsion phantoms. This work represents a significant step toward the development of technologies for frequent breast cancer treatment monitoring in the clinic and potentially at home.","abstract_html":"Neoadjuvant chemotherapy (NAC) is a common breast cancer treatment that involves administering chemotherapy for 3-6 months prior to surgery. This treatment enables more breast-conserving surgeries and even allows for the omission of surgery in some cases. However, about 31% of patients receiving NAC do not respond to the treatment. Therefore, there is a need for real-time methods to predict treatment response and improve patient outcomes. Over the last two decades, diffuse optical imaging has been investigated as a potential solution to this problem. This noninvasive and inexpensive technology uses near or shortwave infrared (NIR or SWIR) light to illuminate tissue, and detects multiply-scattered photons. However, bulky instrumentation and complicated imaging procedures have limited the clinical adoption of this technology. Furthermore, measured biomarkers including oxy- and deoxy-hemoglobin (HbO2 and HHb, respectively), water, and lipid, have had mixed results in terms of prognostic capability. To address these limitations, a new wearable optical probe technology was developed and validated in this project, including a high-optode density NIR probe for monitoring hemodynamics and a first-generation SWIR probe for quantifying water and lipid. Measurements on tissue-mimicking channel flow phantoms confirmed the ability of the NIR probe to quantify absorption contrast in vitro, and a cuff occlusion measurement demonstrated sensitivity to HbO2 and HHb in vivo. Hemodynamic oscillations at the respiratory rate were also explored in healthy volunteers and breast cancer patients as a potential new biomarker. It was demonstrated that traditional and novel breathing-related hemodynamic metrics provide tumor contrast and can potentially track treatment response. A deep-learning algorithm was developed to extract water and lipid concentrations from multi-distance SWIR measurements. The SWIR probe was validated by comparing measured water and lipid concentrations against ground truth values in emulsion phantoms. This work represents a significant step toward the development of technologies for frequent breast cancer treatment monitoring in the clinic and potentially at home.","abstract_has_math":false,"creators":["Spink, Samuel S."],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Roblyer, Darren"],"committee_chairs":[],"committee_members":[],"year":2023,"date_issued":"2023","date_published":"2023","updated_at":"2026-07-24T01:25:01Z","subjects":["Medical imaging","Diffuse optics","Optical probe","Reflectance spectroscopy"],"languages":["en_US"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/2144/46643","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Roblyer, Darren"]},{"key":"dc:creator","label":"Author","values":["Spink, Samuel S."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2023-09-01T18:30:02Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2023-09-01T18:30:02Z"]},{"key":"dc:date.issued","label":"Date","values":["2023"]},{"key":"dc:type","label":"Dc Type","values":["Thesis/Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Medical imaging","Diffuse optics","Optical probe","Reflectance spectroscopy"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en_US"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/2144/46643"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Neoadjuvant chemotherapy (NAC) is a common breast cancer treatment that involves administering chemotherapy for 3-6 months prior to surgery. This treatment enables more breast-conserving surgeries and even allows for the omission of surgery in some cases. However, about 31% of patients receiving NAC do not respond to the treatment. Therefore, there is a need for real-time methods to predict treatment response and improve patient outcomes. Over the last two decades, diffuse optical imaging has been investigated as a potential solution to this problem. This noninvasive and inexpensive technology uses near or shortwave infrared (NIR or SWIR) light to illuminate tissue, and detects multiply-scattered photons. However, bulky instrumentation and complicated imaging procedures have limited the clinical adoption of this technology. Furthermore, measured biomarkers including oxy- and deoxy-hemoglobin (HbO2 and HHb, respectively), water, and lipid, have had mixed results in terms of prognostic capability. To address these limitations, a new wearable optical probe technology was developed and validated in this project, including a high-optode density NIR probe for monitoring hemodynamics and a first-generation SWIR probe for quantifying water and lipid. Measurements on tissue-mimicking channel flow phantoms confirmed the ability of the NIR probe to quantify absorption contrast in vitro, and a cuff occlusion measurement demonstrated sensitivity to HbO2 and HHb in vivo. Hemodynamic oscillations at the respiratory rate were also explored in healthy volunteers and breast cancer patients as a potential new biomarker. It was demonstrated that traditional and novel breathing-related hemodynamic metrics provide tumor contrast and can potentially track treatment response. A deep-learning algorithm was developed to extract water and lipid concentrations from multi-distance SWIR measurements. The SWIR probe was validated by comparing measured water and lipid concentrations against ground truth values in emulsion phantoms. This work represents a significant step toward the development of technologies for frequent breast cancer treatment monitoring in the clinic and potentially at home."]},{"key":"dc:title","label":"Title","values":["Next generation near infrared (NIR) and shortwave infrared (SWIR) wearables for breast cancer imaging"]}]}],"canonical_facts":{"dc:contributor.advisor":["Roblyer, Darren"],"dc:creator":["Spink, Samuel S."],"dc:date.accessioned":["2023-09-01T18:30:02Z"],"dc:date.available":["2023-09-01T18:30:02Z"],"dc:date.issued":["2023"],"dc:description.abstract":["Neoadjuvant chemotherapy (NAC) is a common breast cancer treatment that involves administering chemotherapy for 3-6 months prior to surgery. This treatment enables more breast-conserving surgeries and even allows for the omission of surgery in some cases. However, about 31% of patients receiving NAC do not respond to the treatment. Therefore, there is a need for real-time methods to predict treatment response and improve patient outcomes. Over the last two decades, diffuse optical imaging has been investigated as a potential solution to this problem. This noninvasive and inexpensive technology uses near or shortwave infrared (NIR or SWIR) light to illuminate tissue, and detects multiply-scattered photons. However, bulky instrumentation and complicated imaging procedures have limited the clinical adoption of this technology. Furthermore, measured biomarkers including oxy- and deoxy-hemoglobin (HbO2 and HHb, respectively), water, and lipid, have had mixed results in terms of prognostic capability. To address these limitations, a new wearable optical probe technology was developed and validated in this project, including a high-optode density NIR probe for monitoring hemodynamics and a first-generation SWIR probe for quantifying water and lipid. Measurements on tissue-mimicking channel flow phantoms confirmed the ability of the NIR probe to quantify absorption contrast in vitro, and a cuff occlusion measurement demonstrated sensitivity to HbO2 and HHb in vivo. Hemodynamic oscillations at the respiratory rate were also explored in healthy volunteers and breast cancer patients as a potential new biomarker. It was demonstrated that traditional and novel breathing-related hemodynamic metrics provide tumor contrast and can potentially track treatment response. A deep-learning algorithm was developed to extract water and lipid concentrations from multi-distance SWIR measurements. The SWIR probe was validated by comparing measured water and lipid concentrations against ground truth values in emulsion phantoms. This work represents a significant step toward the development of technologies for frequent breast cancer treatment monitoring in the clinic and potentially at home."],"dc:identifier.uri":["https://hdl.handle.net/2144/46643"],"dc:language.iso":["en_US"],"dc:subject":["Medical imaging","Diffuse optics","Optical probe","Reflectance spectroscopy"],"dc:title":["Next generation near infrared (NIR) and shortwave infrared (SWIR) wearables for breast cancer imaging"],"dc:type":["Thesis/Dissertation"]},"updated_at":"2026-07-24T01:25:01Z"}